vs
EXACT SCIENCES CORP（EXAS）与FORWARD AIR CORP（FWRD）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是FORWARD AIR CORP的1.4倍（$878.4M vs $631.2M），FORWARD AIR CORP净利率更高（-4.5% vs -9.8%，领先5.3%），EXACT SCIENCES CORP同比增速更快（23.1% vs -0.3%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 7.9%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Forward Air Corp是北美领先的轻资产物流运输服务商，核心业务包括加急零担货运、最后一公里配送、多式联运、仓储及供应链解决方案，服务覆盖美加墨地区，主要服务电商、零售、制造、汽车等行业。
EXAS vs FWRD — 直观对比
营收规模更大
EXAS
是对方的1.4倍
$631.2M
营收增速更快
EXAS
高出23.4%
-0.3%
净利率更高
FWRD
高出5.3%
-9.8%
两年增速更快
EXAS
近两年复合增速
7.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $631.2M |
| 净利润 | $-86.0M | $-28.3M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | -0.5% |
| 净利率 | -9.8% | -4.5% |
| 营收同比 | 23.1% | -0.3% |
| 净利润同比 | 90.1% | 22.2% |
| 每股收益（稀释后） | $-0.45 | $-0.90 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFWRD
| Q4 25 | $878.4M | $631.2M | ||
| Q3 25 | $850.7M | $631.8M | ||
| Q2 25 | $811.1M | $618.8M | ||
| Q1 25 | $706.8M | $613.3M | ||
| Q4 24 | $713.4M | $632.8M | ||
| Q3 24 | $708.7M | $655.9M | ||
| Q2 24 | $699.3M | $643.7M | ||
| Q1 24 | $637.5M | $541.8M |
净利润EXASFWRD
| Q4 25 | $-86.0M | $-28.3M | ||
| Q3 25 | $-19.6M | $-16.3M | ||
| Q2 25 | $-1.2M | $-12.6M | ||
| Q1 25 | $-101.2M | $-50.6M | ||
| Q4 24 | $-864.6M | $-36.4M | ||
| Q3 24 | $-38.2M | $-73.4M | ||
| Q2 24 | $-15.8M | $-645.4M | ||
| Q1 24 | $-110.2M | $-61.7M |
毛利率EXASFWRD
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASFWRD
| Q4 25 | -9.4% | -0.5% | ||
| Q3 25 | -3.0% | 2.4% | ||
| Q2 25 | -0.3% | 3.2% | ||
| Q1 25 | -13.6% | 0.8% | ||
| Q4 24 | -122.8% | 12.0% | ||
| Q3 24 | -5.6% | 3.5% | ||
| Q2 24 | -3.8% | -170.2% | ||
| Q1 24 | -16.7% | -12.1% |
净利率EXASFWRD
| Q4 25 | -9.8% | -4.5% | ||
| Q3 25 | -2.3% | -2.6% | ||
| Q2 25 | -0.1% | -2.0% | ||
| Q1 25 | -14.3% | -8.3% | ||
| Q4 24 | -121.2% | -5.8% | ||
| Q3 24 | -5.4% | -11.2% | ||
| Q2 24 | -2.3% | -100.3% | ||
| Q1 24 | -17.3% | -11.4% |
每股收益（稀释后）EXASFWRD
| Q4 25 | $-0.45 | $-0.90 | ||
| Q3 25 | $-0.10 | $-0.52 | ||
| Q2 25 | $-0.01 | $-0.41 | ||
| Q1 25 | $-0.54 | $-1.68 | ||
| Q4 24 | $-4.69 | $-1.69 | ||
| Q3 24 | $-0.21 | $-2.66 | ||
| Q2 24 | $-0.09 | $-23.47 | ||
| Q1 24 | $-0.60 | $-2.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $106.0M |
| 总债务越低越好 | — | $1.7B |
| 股东权益账面价值 | $2.4B | $113.3M |
| 总资产 | $5.9B | $2.7B |
| 负债/权益比越低杠杆越低 | — | 14.89× |
8季度趋势，按日历期对齐
现金及短期投资EXASFWRD
| Q4 25 | $964.7M | $106.0M | ||
| Q3 25 | $1.0B | $140.4M | ||
| Q2 25 | $858.4M | $95.1M | ||
| Q1 25 | $786.2M | $116.3M | ||
| Q4 24 | $1.0B | $104.9M | ||
| Q3 24 | $1.0B | $136.6M | ||
| Q2 24 | $946.8M | $84.9M | ||
| Q1 24 | $652.1M | $152.0M |
总债务EXASFWRD
| Q4 25 | — | $1.7B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.7B |
股东权益EXASFWRD
| Q4 25 | $2.4B | $113.3M | ||
| Q3 25 | $2.5B | $139.8M | ||
| Q2 25 | $2.5B | $151.8M | ||
| Q1 25 | $2.4B | $154.6M | ||
| Q4 24 | $2.4B | $201.7M | ||
| Q3 24 | $3.2B | $226.1M | ||
| Q2 24 | $3.2B | $283.8M | ||
| Q1 24 | $3.1B | $926.1M |
总资产EXASFWRD
| Q4 25 | $5.9B | $2.7B | ||
| Q3 25 | $5.9B | $2.8B | ||
| Q2 25 | $5.8B | $2.8B | ||
| Q1 25 | $5.7B | $2.8B | ||
| Q4 24 | $5.9B | $2.8B | ||
| Q3 24 | $6.7B | $3.1B | ||
| Q2 24 | $6.7B | $3.1B | ||
| Q1 24 | $6.4B | $4.0B |
负债/权益比EXASFWRD
| Q4 25 | — | 14.89× | ||
| Q3 25 | — | 12.05× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.81× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | 1.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASFWRD
| Q4 25 | $151.7M | — | ||
| Q3 25 | $219.9M | $52.7M | ||
| Q2 25 | $89.0M | — | ||
| Q1 25 | $30.8M | $27.6M | ||
| Q4 24 | $47.1M | $-23.2M | ||
| Q3 24 | $138.7M | $51.2M | ||
| Q2 24 | $107.1M | $-45.2M | ||
| Q1 24 | $-82.3M | $-51.7M |
自由现金流EXASFWRD
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | $48.6M | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | $15.7M | ||
| Q4 24 | $10.7M | $-30.5M | ||
| Q3 24 | $112.6M | $40.7M | ||
| Q2 24 | $71.2M | $-59.6M | ||
| Q1 24 | $-120.0M | $-56.7M |
自由现金流率EXASFWRD
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | 7.7% | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | 2.6% | ||
| Q4 24 | 1.5% | -4.8% | ||
| Q3 24 | 15.9% | 6.2% | ||
| Q2 24 | 10.2% | -9.3% | ||
| Q1 24 | -18.8% | -10.5% |
资本支出强度EXASFWRD
| Q4 25 | 3.6% | 1.3% | ||
| Q3 25 | 3.5% | 0.7% | ||
| Q2 25 | 5.2% | 0.8% | ||
| Q1 25 | 4.4% | 1.9% | ||
| Q4 24 | 5.1% | 1.1% | ||
| Q3 24 | 3.7% | 1.6% | ||
| Q2 24 | 5.1% | 2.2% | ||
| Q1 24 | 5.9% | 0.9% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FWRD
| Omni Logistics Segment | $359.8M | 57% |
| Network | $183.9M | 29% |
| Intermodal Segment | $50.2M | 8% |
| Truckload | $41.6M | 7% |
